skip to Main Content

CQDM Partners with MaRS Innovation, Ontario Brain Institute and Ontario Centres of Excellence to Launch Life Sciences Funding Program Within Ontario-Québec Corridor

BOSTON, MA, June 18, 2012 — Together with key partners from Ontario, The Québec Consortium for Drug Discovery (CQDM) is creating a new initiative to fund collaborative life sciences research projects between the two provinces.

A French version of this release is available via CQDM’s website.

This initiative is the first notable and concrete realization of the Ontario-Québec Life Sciences Corridor, announced at the 2011 BIO International Convention. It builds upon two previous pilot projects and existing strengths within the two provinces to increase innovation, productivity, investment and job creation.

Continue Reading

Encycle Therapeutics Launches Ground-Breaking Chemistry Platform

Platform for cyclizing peptides promises to increase efficiency of early-stage drug discovery

BOSTON, June 18, 2012 – Encycle Therapeutics, a MaRS Innovation spin-off company, has created a ground-breaking chemistry platform for cyclizing peptides that promises to increase the efficiency of the early-stage drug discovery process.

Peptides have long been sought after as therapeutics due to their high specificity — they can hit specific cellular targets, especially complex protein-protein interaction targets implicated in cancer, cardiovascular disease and metabolic disorders.

Continue Reading

MaRS Innovation Forms Strategic Drug-Development Partnership with NovoTek Therapeutics Inc. in China

ScarX logoMaRS Innovation (MI), The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek)  have announced a strategic partnership to co‐develop, and bring to the Chinese market, a novel therapeutic cream aimed at reducing scar formation post surgery.

This project was covered in The Globe and Mail on May 7, 2012.

Continue Reading

Federal and Provincial Proof of Principle Programs Support Translational Technology Development

Ontario Centres of Excellence--Where Next HappensTORONTO (August 16, 2010) – MaRS Innovation (MI) is pleased to announce that translational funding to support product development for early-stage technologies from its members has been successfully deployed from federal and provincial sources. At the federal level, three of MI’s commercialization projects have recently received notification of funding from the Canadian Institutes of Health Research (CIHR) Proof of Principle (PoP) program, amounting to approximately $470,000.

Moreover, MI has successfully deployed about $1 million in proof of principle funding received from the Ontario Ministry of Research and Innovation (MRI) through the Ontario Centres of Excellence (OCE). This provincial program was previously managed by the MI founding commercialization partners in the life and physical sciences, BioDiscovery Toronto (BDT) and Technology Transfer Toronto (TTT). MI is grateful that these organizations laid the foundation for provincial proof of principle funding and looks forward to continuing a successful provincial PoP program.

Continue Reading
Back To Top